Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors (GPCRs) to address unmet medical needs. The Company’s most advanced investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn’s disease.

Type
Public
HQ
San Diego, US
Founded
1977
Size (employees)
106 (est)
Arena Pharmaceuticals was founded in 1977 and is headquartered in San Diego, US
Report incorrect company information

Key People/Management at Arena Pharmaceuticals

Amit D. Munshi

Amit D. Munshi

Director, President and Chief Executive Officer
Vince Aurentz

Vince Aurentz

Executive Vice President and Chief Business Officer
Douglas A. Bakan Ph.D

Douglas A. Bakan Ph.D

Executive Vice President, Technical Operations
Chris Cabell M.D., M.H.S. FACC

Chris Cabell M.D., M.H.S. FACC

Senior Vice President, Head of Clinical Development
Preston Klassen M.D., M.H.S

Preston Klassen M.D., M.H.S

Executive Vice President, Research and Development and Chief Medical Officer
Kevin R. Lind

Kevin R. Lind

Executive Vice President and Chief Financial Officer
Show more

Arena Pharmaceuticals Office Locations

Arena Pharmaceuticals has offices in San Diego and Zofingen
San Diego, US (HQ)
6154 Nancy Ridge Drive
Zofingen, CH
4 Untere Brühlstrasse
Show all (2)
Report incorrect company information

Arena Pharmaceuticals Financials and Metrics

Arena Pharmaceuticals Financials

Arena Pharmaceuticals's revenue was reported to be $21.34 m in FY, 2017
USD

Revenue (Q1, 2018)

1.8 m

Net income (Q1, 2018)

(32 m)

EBIT (Q1, 2018)

(31 m)

Market capitalization (15-May-2018)

2.3 b

Closing share price (15-May-2018)

46.7

Cash (31-Mar-2018)

516.1 m
Arena Pharmaceuticals's current market capitalization is $2.3 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

81.4 m37 m38.3 m124 m21.3 m

Revenue growth, %

(55%)4%223%

Cost of goods sold

1.8 m6.4 m8.6 m9.3 m

Gross profit

79.6 m30.6 m29.7 m114.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

3.6 m6.8 m12.8 m8.2 m12.3 m9.2 m9.1 m9.8 m9.5 m19.2 m6.6 m6.5 m1.8 m

Cost of goods sold

460 k831 k1.5 m1.8 m3.2 m1.3 m1.6 m2.4 m851 k882 k2.5 m1.5 m

Gross profit

3.1 m6 m11.3 m6.4 m9.1 m7.9 m7.5 m7.4 m8.7 m18.4 m4.1 m5 m

Gross profit Margin, %

87%88%89%79%74%86%82%75%91%95%62%77%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

221.9 m163.2 m156.2 m90.7 m158.8 m

Accounts Receivable

10.6 m3.7 m4.9 m20.2 m2.4 m

Inventories

3.6 m4.1 m4.2 m6.7 m

Current Assets

248.8 m181.9 m174.8 m119.9 m281.3 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

180.7 m203.3 m200.8 m188.3 m241 m216.7 m181.3 m139.5 m122 m101.6 m79.5 m130.8 m516.1 m

Accounts Receivable

12.4 m1.6 m7.4 m2.9 m12.2 m4.2 m3.5 m6.2 m3.3 m18.3 m1.7 m2.4 m3.3 m

Inventories

10 m11.9 m12.6 m11.9 m11.4 m11 m10.2 m9.1 m9.5 m10.2 m7.1 m7.1 m

Current Assets

206.6 m276.4 m243.7 m209.1 m268.6 m236 m200.2 m160.1 m139.8 m134.9 m92.3 m143.6 m649.9 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(19.4 m)(60.5 m)(108 m)(22.9 m)(92.7 m)

Depreciation and Amortization

7.7 m8.7 m9.8 m9.1 m4.3 m

Inventories

(6.1 m)870 k1.9 m3.2 m

Accounts Payable

Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(17.2 m)(25.3 m)7.5 m(10.7 m)(24.3 m)(26.8 m)(26.4 m)(21.5 m)(27.2 m)(12.5 m)(22.5 m)(32 m)

Depreciation and Amortization

949 k

Inventories

12.6 m11.9 m11.4 m11 m10.2 m9.1 m9.5 m10.2 m7.1 m

Cash From Operating Activities

(29.8 m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information